| Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema MJ Elman, LP Aiello, RW Beck, NM Bressler, SB Bressler, AR Edwards, ... Ophthalmology 117 (6), 1064-1077. e35, 2010 | 1871 | 2010 |
| Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. JA Wells, AR Glassman, AR Ayala, LM Jampol, LP Aiello, AN Antoszyk, ... The New England journal of medicine 372 (13), 1193-1203, 2015 | 1567 | 2015 |
| Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial JA Wells, AR Glassman, AR Ayala, LM Jampol, NM Bressler, SB Bressler, ... Ophthalmology 123 (6), 1351-1359, 2016 | 1029 | 2016 |
| Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema MJ Elman, NM Bressler, H Qin, RW Beck, FL Ferris III, SM Friedman, ... Ophthalmology 118 (4), 609-614, 2011 | 794 | 2011 |
| A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9 Age-Related Eye Disease Study Research Group Archives of Ophthalmology 119 (10), 1439-1452, 2001 | 656 | 2001 |
| Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial JG Gross, AR Glassman, LM Jampol, S Inusah, LP Aiello, AN Antoszyk, ... Jama 314 (20), 2137-2146, 2015 | 623 | 2015 |
| Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results MJ Elman, H Qin, LP Aiello, RW Beck, NM Bressler, FL Ferris III, ... Ophthalmology 119 (11), 2312-2318, 2012 | 521 | 2012 |
| High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. SE Bursell, AC Clermont, LP Aiello, LM Aiello, DK Schlossman, ... Diabetes care 22 (8), 1245-1251, 1999 | 488 | 1999 |
| Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results MJ Elman, A Ayala, NM Bressler, D Browning, CJ Flaxel, AR Glassman, ... Ophthalmology 122 (2), 375-381, 2015 | 476 | 2015 |
| Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial JG Gross, AR Glassman, D Liu, JK Sun, AN Antoszyk, CW Baker, ... JAMA ophthalmology 136 (10), 1138-1148, 2018 | 406 | 2018 |
| Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary … NM Bressler, WT Beaulieu, AR Glassman, KJ Blinder, SB Bressler, ... JAMA ophthalmology 136 (3), 257-269, 2018 | 312 | 2018 |
| Stereo nonmydriatic digital-video color retinal imaging compared with Early Treatment Diabetic Retinopathy Study seven standard field 35-mm stereo color photos for determining … SE Bursell, JD Cavallerano, AA Cavallerano, AC Clermont, ... Ophthalmology 108 (3), 572-585, 2001 | 284 | 2001 |
| Diabetic retinopathy and other ocular findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study LP Aiello, Dcct/Edic Research Group Diabetes care 37 (1), 17-23, 2014 | 272 | 2014 |
| Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial RK Maturi, AR Glassman, D Liu, RW Beck, AR Bhavsar, NM Bressler, ... JAMA ophthalmology 136 (1), 29-38, 2018 | 264 | 2018 |
| Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the diabetic retinopathy clinical research network … EL Ross, DW Hutton, JD Stein, NM Bressler, LM Jampol, AR Glassman, ... JAMA ophthalmology 134 (8), 888-896, 2016 | 232 | 2016 |
| Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment SB Bressler, AR Ayala, NM Bressler, M Melia, H Qin, FL Ferris, CJ Flaxel, ... JAMA ophthalmology 134 (3), 278-285, 2016 | 190 | 2016 |
| Change in diabetic retinopathy through 2 years: secondary analysis of a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab SB Bressler, D Liu, AR Glassman, BA Blodi, AA Castellarin, LM Jampol, ... JAMA ophthalmology 135 (6), 558-568, 2017 | 167 | 2017 |
| Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American Academy of Ophthalmology DK VanderVeen, M Melia, MB Yang, AK Hutchinson, LB Wilson, ... Ophthalmology 124 (5), 619-633, 2017 | 165 | 2017 |
| Five-year outcomes of ranibizumab with prompt or deferred laser versus laser or triamcinolone plus deferred ranibizumab for diabetic macular edema SB Bressler, AR Glassman, T Almukhtar, NM Bressler, FL Ferris, ... American journal of ophthalmology 164, 57-68, 2016 | 165 | 2016 |
| Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol T Extension Study) AR Glassman, JA Wells III, K Josic, MG Maguire, AN Antoszyk, C Baker, ... Ophthalmology 127 (9), 1201-1210, 2020 | 163 | 2020 |
